ISRCTN63226217已完成不适用
An open study to compare the efficacy of ImmunoGlobulin administered SubCutaneoulsy (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS)
The Walton Centre NHS Foundation Trust (UK)0 个研究点目标入组 12 人开始时间: 2011年3月10日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Intervention group:
- •1.1. Diagnosis of CRPS according to the 'Bruehl' criteria
- •1.2. Recruited from a previous RCT in London, responding better to intravenous immunoglobulin (IVIG) than normal saline
- •1.3. At least a 24h average pain intensity of 6 over one week (one day of a lower pain intensity of 5 acceptable). Pain intensity must be judged as stable by the principal investigator (PI)
- •1.4. Patients and matched controls should have used routine medications before enrollment including gabapentin and/or pregabalin, duloxetin and/or venlaflaxine, a tricyclic antidepressant, lignocaine patches, both a strong and weak opioid in an appropriate dose without sufficient benefit.
- •1.5. Patients who wish not to follow recommendations of the trial team as to receiving concomitant treatment according to best medical care will nevertheless be suitable for enrollment.
- •1.6. Aged 18 years or over
- •2. Control group:
- •2.1. Selected from patients seen at the Walton Centre over the prior 18 months
- •2.2. Matched for:
- •2.2.1. Age +/10 years
- •2.2.2. Sex
- •2.2.3. Average 24 h pain intensity and acute limb activity related pain intensity +/2 points (but not below 5 on the NRS)
- •2.2.4. Disease duration +/18 months
排除标准
- •1. All patients (cases and controls):
- •1.1. Have evidence of significant organic disease on history or physical examination, which may be severe enough to prevent the patient from being able to complete the study
- •1.2 Suffer from another severe chronic pain syndrome such as fibromyalgia which may in the judgement of principle investigator hinder the appropriate assessment of pain from CRPS
- •1.3 Have a history of abuse or are currently abusing alcohol or drugs [using DSMIV criteria]
- •1.4. Have a psychiatric disorder which may in the judgement of the site investigator interfere with successful study participation
- •1.5. Are unwilling or not able to complete daily diaries
- •1.6. Do not understand the psychological questionnaires because appropriate validated translations into the patient's language are not available
- •2. Intervention group:
- •2.1. IgA serum levels within normal ranges. All patients in the SCIG group have already been tested for their IgA serum levels which were normal in all cases.
- •2.2. Patients with progressive renal failure and any patient requiring IVIG for another disorder
- •2.3. Treatment will be deferred in patients with an infection such as cold, flu or infected pressure sores until the infection has resolved because IG is contraindicated in cases of untreated bacterial infection
- •2.4. For the following patients in the SCIG group suitability for participation needs to be discussed with a specialist consultant:
- •2.4.1. Patients with compensated renal failure, patients suffering from epilepsy
- •2.4.2. Patients with a history of stroke or myocardial infarction
- •2.4.3. Patients with a known procoagulatory or bloodhyperviscosity disorder
- •2.4.4. Patients on loop diuretics
- •2.4.5. Patients with cancer other than basal cell carcinoma within the last 5 years. Those patients who have received definite treatment, such as curative surgery, with no known recurrence can be included without further discussion
研究者
相似试验
进行中（未招募）
1 期
An open study to compare the efficacy of immunoglobulin administered subcutaneoulsy (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS) - SCIG in CRPS over 12 monthsComplex Regional Pain Syndrome (CRPS)EUCTR2009-015242-30-GBThe Walton Centre for Neurology and Neurosurgery NHS Trust12
已完成
不适用
A pilot study the effectiveness of immune globulin for ALI / ARDSJPRN-UMIN000005422Division of Respirology, department of internal medicine, Jikei University Hospital10
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals’ Infanrix-IPV+Hib™ vaccine.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases.EUCTR2011-005868-25-Outside-EU/EEAGlaxoSmithKline Biologicals985
进行中（未招募）
不适用
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants.Primary immunisation of healthy infants in the first year of life against poliomyelitisEUCTR2011-003167-30-Outside-EU/EEAGlaxoSmithKline Biologicals1,101
进行中（未招募）
不适用
Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. - PRIMAVERAInfection by HPV 6, 11, 16, 18EUCTR2011-006002-27-FRCHU de Bordeaux